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I review here the history of inhibition of gastric acid. References are
limited to books and reviews in which detailed citations can be found.
ANTACIDS
In ancient times, acids were not understood in the modem chemical sense but merely
as bitter sour liquids [1]. Some foods were thought acidic, and if the stomach had an
ulcer, everything acrid was to be avoided and soothing remedies such as starch and milk
used. Antacids neutralize, rather than inhibit, acid secretion but could not be rationally
prescribed until acids were understood in the modern chemical sense. Hydrochloric acid
has been known since the early fifteenth century, thought to be in the stomach by
Paracelsus in the sixteenth and by Van Helmont in the seventeenth century, but it was not
until 1823 that Prout definitively identified free hydrochloric acid in the gastric juice of
man and animals and made quantitative measurements ofits concentration.
Antacids became widely used only this century, especially in association with Sippy-
type diets for ulcers [2]. As recently as the 1960s, orthodox gastroenterologists believed
that gastric acidity was reduced by minimizing the amount ofacid-stimulating foods such
as protein and increasing the amount ofacid-inhibiting foods such as fats. It was thought
that gastrin release was reduced by limiting meals to 150 ml to prevent antral distension
and by forbidding secretagogues such as meat juices, coffee, caffeine-containing bever-
ages and alcohol. Moreover, since the patient on such a diet might become frustrated and
then hypersecrete acid if he saw normal meals that were forbidden, patients were not
allowed tojoin the family atmeal times [2].
Certainly doctors have used antacids for thousands of years to treat patients' symp-
toms, and both doctors and patients have generally been satisfied with this treatment.
Half the adults in the United States have used antacids, and a quarter have taken two or
more doses per month. Doctors are even more convinced than patients of the helpfulness
of antacids in relieving symptoms. Nevertheless, there is little evidence in the double-
blind, randomized controlled trials that antacids do relieve ulcer symptoms, and in the
conventional doses, they are probably no more than a logical placebo [3]. By contrast,
antacids have now been shown repeatedly to be more effective than placebo in healing
duodenal ulcers, in the range of efficacy of H2 blockade. Although the classical study
used over a 1000 mmol/day, lower doses have been tried and in further trials were found
effective down to around 200mmol/day [3, 4].
INHIBITION
Inhibition. The term inhibition is all too often used loosely and without making clear
the precise extent of the inhibition: of what function, from what level, to what level, by
aTo whom allcorrespondence shouldbeaddressed: Department ofSurgery, Royal Postgraduate
Medical School, Hammersmith Hospital, London W12 ONN, England. Tel: (44) 181-743-2030,
Ext. 2035; Fax: (44) 181-740-3179.
97Baron: History ofacid inhibition
what percentage, with what inhibitor, for what purpose. Rational use of inhibitors could
occur only when one had a clear pathophysiological model of duodenal ulcer and its
hypersecretory state, when there were dose-response data in patients before and after the
inhibitor and with assessments of ulcer healing and/or follow-up with or without mainte-
nance treatment. It is convenient to begin with Schwartz, who in 1910 postulated the bat-
tle between the autodigestive power of gastric juice versus mucosal resistance: ulcer for-
mation was likely if the acid was increased, and ulcer healing could be achieved by
decreasing the acid [5].
Test meals. In 1912, Moynihan claimed that 70 percent of patients with duodenal
ulcers had hyperchlorhydria or hyperacidity, a claim based on test meals in 20 patients
with duodenal ulcer by Adams (1911). However, there are now ample data that the
ranges of maximum acidity in normal subjects and in patients with duodenal ulcer over-
lap completely, whether after test meals, food, alcohol, caffeine or submaximal histamine
[5]. In the absence of a threshold of acidity, there was no appropriate target figure to
which inhibitors could be directed, and patients with duodenal ulcer could not be man-
aged successfully.
Basal secretion. The first careful data on basal interdigestive secretion were pro-
duced by Carlson in 1912, allowing Galambos in 1926 to demonstrate basal hypersecre-
tion in duodenal ulcer disease [5]. Overnight secretion was first measured by Chalfen in
1928, and by 1935, Winklestein had confirmed nocturnal hypersecretion in duodenal
ulcer disease [5].
Although early studies claimed that patients with duodenal ulcer always produced
some acid at rest, it is now clear that basal anacidity does not exclude duodenal ulcer dis-
ease. Measurements of 12-hr overnight secretion are more difficult than in a one-hr
morning basal collection, and both show poor repeatability [5]. However, about one in
four patients with duodenal ulcer do secrete more than the upper limit of normal, so that
basal acid output has been used as a criterion for measuring the acid-lowering efficacy of
an inhibitor [5]. Indeed, one of the earliest modalities of acid inhibition was neither phar-
macological nor surgical but rather was physical with radiotherapy, as used in Chicago
from 1937. The acid criterion compared with recurrence was achlorhydria after a sub-
maximal agonist. Ifachlorhydria was induced, then ulcers healed and did not recur unless
acid returned. Only four percent of 1485 patients developed achlorhydria for two years or
longer; their peptic ulcers invariably healed and remained healed [2]. Similarly, in the
only controlled trial of radiation (Levin, 1969), patients whose ulcers recurred were those
with continuous basal acid secretion, whereas those who after a period of basal achlorhy-
dria showed acid secretion only intermittently did not develop recurrence of their ulcers
[2]. A different physical acid-lowering treatment was gastric freezing, which had to be
abandoned because sustained acid inhibition could be achieved only with marked damage
to the gastric mucosa.
Maximal acid output. After the introduction by Kay in 1953 of his augmented his-
tamine test measuring maximum histamine-stimulated acid, it was soon possible to show
that measurements of peak acid output in response to maximal doses of histamine (or
histalog or pentagastrin) were about twice normal in patients with duodenal ulcer and that
the proportion ofpatients with duodenal ulcer in the diagnostic hypersecretory range was
now about a third [5]. It was also then possible 30 years ago to demonstrate a threshold of
peak acid output of about 15 mmol/hr, below which duodenal ulcers were not found
(Figure 1) [6]. This functional discrimination paralleled the morphology of the stomach
[5].
It was already known that the number ofparietal cells in patients with duodenal ulcer
was twice normal, that half the stomachs attached to duodenums with ulcer had parietal
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Figure 1. The ranges ofpeak acid output after an augmented histamine test in normal sub-
jects and patients with duodenal ulcer. From Baron (1963) [7] by permission of Clinical
Science.
cell numbers above the upper limit ofnormal and that the threshold parietal cell mass was
1x109, below which duodenal ulcers were not seen post-mortem [5]. With this new
threshold model, it was clear that any inhibitor, whether physical, surgical or pharmaco-
logical, that lowered acid output appropriately to below 15 mmol/hr, would induce heal-
ing of a duodenal ulcer. The ulcer would stay healed if acid remained below this thresh-
old but might recur if acid returned to the previous higher level [5]. This model has been
tested and supported world-wide with one notable exception (Figure 2) [7].
ACID-LOWERING OPERATIONS
Vagotomy. When Dragstedt was appointed Associate Professor of Surgery in the new
University ofChicago School ofMedicine, he had spent the whole of his undergraduate,
postgraduate and professional life as a physiologist and had never been a surgeon even at
a resident or intern level [8, 9]. His scientific approaches to a surgical solution to the
problems of duodenal ulcer have been discussed elsewhere [8, 9], but it is important to
point out that his human patients were studied before and after vagotomy and at follow-
up with as precise measurements ofgastric acid as were available to him at that time and
had been used by him in the necessary preliminary animal experiments. Thus in 1950,
Dragstedt published [10] the 12-hour overnight secretions of 19 patients who had been
followed up for two to seven years and compared these with their pre- and post-operative
studies. Data were given for each patient for volume, free acidity and acid output.
Dragstedt [11] used as his main criterion for completeness of vagotomy a reduction of
overnight acid output of greater than 60 percent and a negative secretory response to
insulin hypoglycemia. None of the 142 patient who met these criteria had persistent or
recurrent ulcer symptoms, but five ofthe 18 whose tests showed incomplete vagal section
did have persistent or recurrent ulcer symptoms.
It is not surprising that 50 years later we use other criteria ofcompleteness ofvagoto-
my. We know that nocturnal gastric acid is a poor discriminant between patients with
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duodenal ulcer and healthy volunteers and that it is poorly reproducible [12]. Today we
would also look at maximal acid output and insulin or sham-feed stimulated acid output.
Probably the most complete data are those from Copenhagen, where Kronborg fol-
lowed 99 percent of500 patients who had duodenal acid treated by truncal vagotomy and
drainage six to eight years before. He used the many previously published criteria but
also performed discriminative analysis to place the highest possible proportion of recur-
rence and non-recurrence in relationship to a critical level of secretion. One of his key
findings was that those patients who were left 10 days after operation with peak acid out-
put after histamine greater than 21 mmollhr had a 25 percent recurrent ulcer rate com-
pared with only five percent if they produced less than 21 mmo/hr. Clearly, there are
only two reasons why patients should have high residual maximal acid output. Either they
were hypersecreters before the operation or the operation had achieved inadequate reduc-
tion in acid output. Kronborg's data showed that those who were secreting greater than
46 mmol/hr before the operation had a 21 percent recurrent ulcer rate compared with five
percent in those who secreted less than this output. Most interesting of all are those
patients where the vagotomist achieved greater than 68 percent reduction in maximal
acid output; they had only a two percent recurrence rate compared with 16 percent with
less than 68 percent acid reduction [5, 13, 14].
Insulin tests. Dragstedt used the Hollander insulin test routinely [10], but both his
criteria and his interpretation were based on the then current all-or-none judgments.
Studies since then, both in healthy volunteers and in patients with duodenal ulcer, sug-
gested that the acid response to insulin is both dose-dependent and hypoglycemia-depen-
dent and not all-or-none [5]. Moreover, not only does insulin hypoglycemia provide a
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quantitative glycopenic stimulus, but it also produces a quantitative vagal response that
can be expressed as peak acid output after insulin in mmol/hr and not merely as a positive
or negative result assessed by the peak or rise in acidity in mmol/I [5].
The second problem is also all-or-none. Dragstedt accepted the then current view
that "in man, apparently, the persistence of a small vagus fibre after section of two of the
larger vagal trunks permits the continued excessive night secretion characteristic of the
ulcer patient. The remaining vagus fibre appears to be able to activate the entire glandu-
lar apparatus, acting presumably through the submucus plexus of Meissner" [10].
However, subsequent animal studies have suggested instead that after vagotomy, the fall
in peak acid output after insulin is related to the extent of acid-secreting mucosa dener-
vated, and the residual acid output after insulin or sham-feed is an expression of residual
vagal innervation [5].
Using this now standardized methodology of quantitative interpretation, and correc-
tions of juice volume (VG) for pyloric loss and duodenal reflux, it was possible for
Hobsley's group [15] to show that patients with duodenal ulcer always had VG greater
than 140 ml/hr before operation. All patients who after vagotomy had VG less than 140
ml/hr remained symptom free, but of those men with VG greater than 140 ml/hr (that is,
within the preoperative range), halfdeveloped recurrent ulcers.
The use of acid secretion tests (basal, maximal, insulin or its safer successor sham-
feed) has elucidated the nature of acid inhibition achieved by the various vagotomies. It
has also improved the technique of the surgeon by comparing trained surgeons with
trainees, trainees' improvement during their training, the learning phase when a surgical
department first uses a new vagotomy, as well as comparisons between the acid inhibition
achieved by general surgeons and by specialists in gastric surgery [5, 16]. It was thus
possible to assess the efficacy of the latest approach to vagotomy, by laparoscopy, show-
ing inhibitions of79 percent ofbasal acid output and 83 percent ofpeak acid output after
insulin [17].
Resection. The percentage reduction in basal and maximum acid outputs after the
various gastric resections, with or without vagotomy are, like vagotomy alone, directly
correlated with non-recurrence ofthe ulcer. (Figure 3) [13, 14].
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Figure 3. Non-recurrence of duodenal ulcer and percentage reduction of maximal acid output
after gastric operations. Data ofBaron (1973 and 1974) [13, 14].
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OperationsforZollinger-Ellison syndrome. When it became clear that the Zollinger-
Ellison syndrome of intractable peptic ulcer, basal hypersecretion and pancreatic tumor
was usually due to a gastrinoma, then it became possible in some patients to avoid the
previous usual procedure of total gastrectomy and instead cure the patient's ulcer disease
from acid and gastrin hypersecretion by removal of the gastrinoma alone.
ACID-INHIBITOR DRUGS
It is now clear that the ulcer-healing properties of an acid-inhibiting drug is a strict
function of the reduction of acid and acidity achieved, whether the drug blocks the acetyl-
choline Ml or the histamine H2 receptor on the surface ofthe parietal cell, or the intracel-
lular enzyme responsible for acid production. In the last 30 years, there have been many
double-blind, placebo-controlled trials of acid inhibitors in healing ulcers and preventing
relapse. Many of these studies were done in countries with low placebo healing rates of
30 percent, so that large numbers ofpatients were not needed in these trials.
Anti-receptoracid inhibitors
Anticholinergics. Acetylcholine receptors are classified as nicotinic and muscarinic
(with several subtypes). The old, classical anti-muscarinics (such as atropine) are not
selective, because even if atropine is a potent and specific muscarinic antagonist, it is not
subtype specific. Many non-subtype muscarinic receptor-antagonists have been synthe-
sized since 1950 as acid inhibitors. Few have been effective in duodenal ulcer disease,
partly because of the difficulty in finding an optimum effective dose, defined as just less
than the dose in a particular patient that produces side effects [2-4]. Nevertheless, there
were two convincing studies. The first by Sun in 1964 [18] was a double-blind, 18-month
maintenance study with glycopyrronium, 1 mg, four times a day. The second by Walan in
1970 was a two-year maintenance therapy with L-hyoscyamine: data were provided for
basal and maximal acid output before, during and after treatment [19]. Patients varied in
the reduction of acid output that could be achieved by a maximum tolerable optimum
effective dose of antimuscarinic; ulcer recurrence was associated with non-reduction of
acid secretion (less than 23 percent); prevention of ulcer recurrence was associated with
adequate reduction ofacid secretion (greater than 32 percent).
Pirenzipine was the first selective anti-muscarinic drug to be marketed, and it binds
with higher affinity to Ml than to other muscarlinic receptors. Pirenzipine's acid inhibito-
ry power allows it to heal peptic ulcer significantly more effectively than placebo in a
dose-dependent fashion and has a maintenance effect, but these properties are less power-
ful than those of H2 blockade. Nevertheless, combination of an H2 receptor blocker and
antimuscarinic possess both theoretically and experimentally a greater anti-secretory
effect than either alone. This combination has been used clinically, but rarely since the
availability ofomeprazole (see below).
H2 receptor blockers. There is little need here to do more than point out that H2-
receptor blockers such as cimetidine and ranitidine will heal about 80 percent ofduodenal
ulcers in four to six weeks and almost 100 percent ifcontinued for three months; mainte-
nance therapy will keep about 80 percent ofduodenal ulcers in remission for a year, and
their clinical efficacy parallel their acid inhibitory property [3, 4].
Intracellular enzyme inhibitors. The enzyme carbonic anhydrase catalyzes the
removal of bicarbonate from the cell and was once thought to be responsible for H+ pro-
duction from H20 in the parietal cell. The first carbonic anhydrase inhibitor to be identi-
fied was sulphanilamide in 1940. Acetazolamide was synthesized in 1950 but reduced
acid only slightly, and there have been few reports ofany ulcer-healing efficacy.
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Once it became clear that H+/K+-ATPase was the enzyme regulating the production
ofhydrochloric acid at the secretory surface ofthe parietal cell, it was possible to synthe-
size gastric proton pump inhibitors such as omeprazole, a substituted benzimidazole.
Omeprazole gives a dose-dependent inhibition of acid secretion of about 20-95 percent,
and a four-week duodenal ulcer healing ranging from 50-97 percent with doses of 10-80
mg daily [4].
ULCER HEALING BY APPROPRIATE ACID SUPPRESSION
The threshold model has been tested not only with various acid-lowering operations
and radiotherapy but also with antisecretagogues. If basal pH was greater than 3 both
before and one week after starting pirenzepine 100 mg daily, three of seven patients with
duodenal ulcerrelapsed in 12 months; with pH greater than 3 only after one week, one of
eleven relapsed; and with pH greater than 3 both before and after pirenzepine, none
relapsed [20]. With cimetidine, five patients whose ulcers failed to heal after six weeks of
1500 mg daily had pre-treatment basal acid output (11.2 mmollhr), thrice those of heal-
ers (3.4 mmol/hr) [21]. For peak acid output, the one-week healing was significantly
higher (33 percent) with peak acid output less than 36 mmollhr compared with 14 per-
cent with peak acid output greater than 36 mmol/hr [22].
Overall, the proportion of duodenal ulcers that heal after two or four weeks of any
acid suppresant treatment is strictly correlated with the percentage reduction of24-hr gas-
tric acidity [23] (Figure 4), and further meta-analyzes yielded clear postulates such as that
all duodenal ulcers would heal in four weeks if intragastric pH was kept above three for
more than 18 hr aday (Figure 4) [24].
Total inhibition of acid and pepsin by operation drugs does not apparently interfere
with normal digestion in the intestine but will lead to failure of the body to kill ingested
100 m
3 <~~~~~~~~~~~0
p< 0*0001
-~~~~~~~~~~~
,80a c h
4) b eQ
4, bU'
0-
I 40.
rp<.0005 - - -
80
60 --
1.0
Suppression of noctumal acidity
A
2 8
, 20 40 60 so 00 L4t a 9 v -
0 30 40 50 60 70 80 90 100
Suppression of 24h czcidity (0/0)
Figure 4. Correlation ofsuppression of24 hr (and nocturnal) intragastric acidity and rate
of healing of duodenal ulcer after four weeks. Open circle: placebo; Triangle: enprostil;
Diamond: antacid; Filled circle: H2 blockers (a, b, c, d, f, g, j: cimetidine; m: famotidine; c:
oxmetidine; e, h, k: ranitidine); Open square: omeprazole (1: 20 mg; 2: 30 mg; 3: 40 mg; 4: 60
mg mane). From Jones et al. (1987) [23] by permission of Gut.
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bacteria with acid and, therefore, increase the risk of infective enteritis. However,
removal of the parietal cells by total gastrectomy will remove intrinsic factor and
inevitably produce B12 deficiency when the body stores are exhausted: B12 deficiency has
not yet been seen with long-term acid inhibitor drugs. Powerful acid inhibitors will lead
to increased gastrin release, which in animals has been associated with enterochromaffin
cell hyperplasia and carcinoid tumors, but such tumors have not been seen in humans on
long-term antisecretagogues.
ACID INHIBITION OR HELICOBACTER PYLORI ERADICATION
A century of acid-lowering operations and a half century of acid inhibitors have
clearly shown that appropriate inhibition of acid, bringing it below a certain threshold,
will heal duodenal ulcers, and if the acid inhibition is maintained by indefinite continua-
tion of acid-lowering tablets, or by continued adequacy of the vagotomy, then ulcers will
not recur. After ulcer healing, acid hypersecretors remain hypersecretors and at risk of
recurrent ulceration, so maintenance tablets or an operation may be indicated.
The clear success of these acid-lowering treatments eventually convinced clinicians
that excess acid was a necessary factor for the production of duodenal ulcers. However
this, was not the end ofthe story for ulcerologists because there was no adequate explana-
tion for the duodenal changes produced by excess acid, or indeed the cause of the excess
acid.
Duodenal ulcer develops from duodenitis, which develops especially in abnormal
mucosa in the duodenum. This abnormality has long been recognized as a mucosa con-
taining not the normal cell types of duodenum but showing gastric metaplastic cells,
which can be produced experimentally by increasing duodenal acidity [25]. Gastric het-
erotopia was never found in duodenal mucosa from gastric resection if the preoperative
maximal acid output was less than 10 mmol/hr, was rare at less than 20 and became
increasingly common the higher the acid output [26, 27]; it has also been correlated with
fasting gastric pH and not seen unless the pH was below 2.5 [28].
Not long after the original isolation in 1983 by Warren and Marshall ofHelicobacter
pylori, this bacterium was held to be the prime cause of non-autoimmune gastritis, and
indeed, Marshall produced gastritis in himselfby swallowing H. pylori.
Antral gastritis was long known to be associated with duodenal ulcer disease, and it
was therefore inevitable that antral H. pylori infection has been found in almost every
patient with duodenal ulcer. Acute infection with H. pylori may lead to transient reduc-
tion in acid output, which can become permanent if gastric atrophy develops in the body
of the stomach. It is still unclear whether mild inflammation of the antrum, which
decreases D cell release of somatostatin and thus increases gastrin and histamine release,
is a cause ofgastric acid hypersecretion.
Marshall's group found H. pylori in areas of focal metaplasia in the duodenum, and
our current model of duodenal ulcer disease has two components: acid-induced duodenal
gastric metaplasia infected with H. pylori. This model, that H. pylori is responsible for
about 95 percent ofduodenal ulcers, which can develop only if there is acid-induced gas-
tric metaplasia in the duodenum, can be tested by the efficacy oferadication ofH. pylori,
which not only leads to healing of almost every duodenal ulcer but also prevents relapse
ofthe ulceration.
Acid inhibition, whether medical or surgical, whether for healing or for maintenance,
is no longer the treatment of first choice for most duodenal ulcers. However, acid sup-
pression is now part of many regimes for eradicating H. pylori. Although acid inhibitors
by themselves do not eradicate H. pylori, one ofthem (omeprazole) does have the proper-
ty of suppressing (but not eradicating) H. pylori. Moreover, omeprazole's chiefrole in an
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H. pylori eradication scheme is to raise the intragastric pH and increase the bactericidal
effect ofantibiotics such as amoxycillin and clarithromycin, which show considerable pH
sensitivity in their minimum inhibitory concentrations for killing H. pylori both in vitro
and in vivo [29]. Clearly, acid inhibitors will remain the treatment of choice to heal and
maintain in remission that five percent ofduodenal ulcers that are not related to H. pylori
and those peptic ulcers that are induced by non-steroidal anti-inflammatory drugs, quite
apart from their continued role in the treatment of gastro-esophageal reflux disease.
Naturally, there are other non-acid aggressive factors than H. pylori and non-steroidal
anti-inflammatory drugs, such as smoking and stress (burns, polytrauma, organ failure).
There are also ulcer-healing treatments that are neither anti-secretory nor lethal to H.
pylori, for example carbenoxolone, prostaglandins and sucralfate.
FINALE
In New Orleans, on April 26, 1975, Dragstedt delivered his last paper. In his
address, published posthumously [30], he reviewed his truncal vagotomy and welcomed
the newer vagotomies as the likely best routine treatment of duodenal ulcer, which by
lowering acid would reduce the morbidity and mortality of the disease. Indeed, his very
last words were "Death is the worst thing that can happen to an ulcer patient. The game
then is over." As a physiologist turned surgeon, he would, I hope, have welcomed the
replacement ofelective vagotomy by acid-lowering drugs. But I wonder ifhe would have
recalled his first paper, 60 years before, in 1917, when he grew bacteria from ulcers,
which were caused, therefore, not by acid but by an infection [31].
Dragstedt's acid-lowering vagotomy (a surgical triumph of applied physiology) led
to acid-lowering drugs (medical triumphs of applied pharmacology) [32], and these two
treatments have been effective in healing peptic ulcers over this last half century. By
some bizarre fate, these acid-lowering treatments (which healed but did not cure the
underlying ulcer disease) have been largely superseded by the vindication of Dragstedt's
first ulcer model, constructed in his early twenties, that these ulcers are caused by bacte-
ria (now identified on culture as H. pylori) and, therefore, are curable by eradication with
anti-bacterials.
We now know that both acid hypersecretion and these bacteria are needed for duode-
nal ulcer formation. Dragstedt's bacterial model [31] was not capable ofproofin 1917 in
the absence of today's culture techniques and antibacterials, but his later (acid hyper-
secretion) model was both testable and treatable. Few scientists are right twice and differ-
ently in their life work. Dragstedt was, and we rightly commemorate him.
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